Traditional instrumental variables (IV) econometric methodologies often fail to take into account response heterogeneity. Response heterogeneity based on characteristics not observed by the researcher can create a heterogeneity in the self-selection process. For instance, one group of people who elect to receive surgery may have knowledge of a family history where surgery is typically successful, whereas another group may elect not to receive surgery due to a different family history. If this information is unobservable to the researcher than an analysis of the average of effect of surgery may be biased. In the medical context, traditional IV assumes that:

- treatment effects are constant conditional on observed characteristics, or
- if treatment effects are heterogeneous, patients or physicians cannot anticipate these effects and use this information to select the most beneficial treatment.

In traditional IV, the treatment parameter gives researchers a local average treatment effect (LATE). But can a researcher characterize a heterogeneous response using IV? A solution to this problem is presented by Basu, Heckman, Navarro-Lozano and Urzua in a 2007 *Health Economics *paper*. *They use a local IV to estimate marginal treatment effect (MTE) parameters.

**Basic Econometrics Review**

Let us assume that a person will have two different outcomes based on whether or not they are treated:

- Y
_{1}= μ_{1}(**X**) + U_{1} - Y
_{0}= μ_{0}(**X**) + U_{0} - Δ = Y
_{1}– Y_{0}= {μ_{1}(**X**) -μ_{0}(**X**)} + (U_{1}– U_{0}) - Y=μ
_{0}(**X**)+D*{μ_{1}(**X**)-μ_{0}(**X**)} + {D(U_{1}– U_{0}) + U_{0}}

The variable *Y _{1 }*represents the outcome if the person is treated and

*Y*

_{0}represents the outcome if they are not treated. We only have one observation per person, however, since we cannot observe the counterfactual. If we could observe the counterfactual, Δ would give us the effect of the treatment for each person. Unfortunately we only observe

*Y*. The dummy variable

*D*is equal to unity if the person is in the treatment group and zero otherwise. If there were a randomized trial where people are randomly placed into the treatment and control groups, it would be easy to estimate the treatment effect by comparing the mean outcomes of the treated and control groups. We could examine the mean outcomes for individuals with similar characteristics to determine the treatment parameter by subgroup. However, if individuals can select whether or not to be treated, the error term–which may be composed of unobserved heterogeneity in the effectiveness of the treatment–may be correlated with the regressors that impact the outcome.

The traditional solution to the endogeneity problem is IV. Let * X* be the set of regressors and

*represent the instruments. “LATE computes the mean gain to those induced to switch from no treatment to treatment by a change in*

**Z****from**

*Z***to**

*z***‘.”**

*z*- LATE={E(Y|
**X**=**x**,**Z**=**z**‘)-E(Y|**X**=**x**,**Z**=**z**)} / {P(D=1|**X**=**x**,**Z**=**z**‘) – P(D=1|**X**=**x**,**Z**=**z**)}

**Marginal Treatment Effect (MTE)**

Developed by Björklund and Moffitt (1987) and furthered by Heckman (1997), the MTE measures “the average gain to patients who are indifferent between receiving *treatment 1 *[the treatment]* *versus *treatment 0* [the control] given * X* and

*.” The benefit of using MTE is that one can calculate the marginal treatment effect for different subgroups based on the propensity score. This places a high degree of reliance on the accuracy and precision of the propensity score in order to determine these subgroup treatment parameters.*

**Z**Let *V* denote a latent variable which measures the difference in benefits from being in the treated and control groups. Treatment choice can be modeled as follows.

- V= μ
_{v}(**Z**,**X**) + U_{v} - E(U
_{v})=0 - D=
**1**(V>0)

The authors use a propensity score to determine the probability of selecting treatment.

- P(
**z**,**x**)=P(D=1|**Z**=**z**,**X**=**x**) = P(U_{v}> -μ_{v}(**z**,**x**)) = 1 – F_{Uv}(-μ_{v}(**z**,**x**)) *F*is the cdf of U_{Uv}()_{v}.

Now we can define MTE to be:

- MTE(
**x**,**z**)=E(Δ|**X**=**x**,**Z**=**z**, V=0) - =E(Δ|
**X**=**x**,**Z**=**z**, U_{v}=-μ_{v}(**z**,**x**)) - =μ
_{1}(**x**) -μ_{0}(**x**) + E{U_{1}– U_{0}|U_{v}=-μ_{v}(**z**,**x**)} - =μ
_{1}(**x**) -μ_{0}(**x**) + E{U_{1}– U_{0}|U_{D}= F_{Uv}(-μ_{v}(**z**,**x**))}

where F_{Uv}(U_{v})=U_{D}. The last equation after the ‘|’ is a monotonic transformation of the terms after the ‘|’ in the third equation.

**Local IV (LIV)
**

The LIV estimates the derivative of the expected outcome conditional on observed characteristics *and *the probability of electing to be in the treatment group, *E(Y| X=x, P(z,x))*, with respect to the probability of treatment,

*P(*. The term E(Y|

**z,x**)**X**=

**x**,

**P(**

**z,x**)) is defined as follows:

- E(Y|
**X**=**x**,**z,x**))=E{ DY_{1}– (1-D)Y_{0}|X=x, P(**Z**,**X**)=P(**z**,**x**)} - =μ
_{0}(**x**) + P(**z**,**x**){μ_{1}(**x**) -μ_{0}(**x**)} + E{U_{0}|P(**Z**,**X**)=P(**z**,**x**)} + P(**z**,**x**){E{U_{1}-U_{0}| P(**Z**,**X**)=P(**z**,**x**), D=1) - =μ
_{0}(**x**) + P(**z**,**x**){μ_{1}(**x**) -μ_{0}(**x**)} + K{P(**z**,**x**))

The term *K(P( z,x))* is a general function of the propensity score,

*P(*. Often, K() will be a polynomial of the propensity score. The MTE can be computed mathematically as below:

**z**,**x**)- {∂E(Y|
**X**=**x**,**z,x**)) / ∂P(**z,x**)} |_{1-P(x,z)=}U_{D} - = μ
_{1}(**x**) -μ_{0}(**x**) + ∂K(P(**z**,**x**))/∂P(**z**,**x**)

The equation above “…is implemented by regressing the outcome Y on all covariates [**X**], the propensity score, the interaction of the propensity score with all covariates and a polynomial on the propensity score.” This procedure is carried out in the paper empirically by applying these methods to data on breast cancer patients and their choice of breast-conserving surgery with radiation compared to mastectomy.

- Basu A, Heckman JJ, Navarro-Lozano S, Urzua S (2007) “Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients,”
*Health Economics*v(16), pp. 1133-1157.

## 1 Comment

Comments are closed.